Close Menu

miRNA

Papers of Note: Jul 9, 2009

Premium

RNAi-Related Papers Published June 2009

Using a technique called HITS-CLIP, researchers from Rockefeller University have created a map of microRNA-messenger RNA interactions in the mouse brain.

The release of the data comes on the heels of a publication in Cell showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, which Mirna's CEO said bolsters the company's strategy.

The method, which is detailed in the current issue of Genome Biology, involves using the mean expression value of all expressed miRNAs in a given sample.

The company's lab is cleared in 48 states. The firm also said that it could earn $17 million through a license with Prometheus Laboratories.

The firm launched three microRNA-based tests during the fourth quarter, and posted a profit due to a capital gain on the sale of Auction Rate Securities to Credit Suisse. However, Rosetta only has enough cash to fund operations through mid-2010 and said that it may seek to raise additional funds.

An Affy spokesperson said the firm's interest in the market is an extension of its gene-expression profiling play, and said several "key advantages" over rival tools could enable it to profit in the market, which is poised to grow 25 percent through 2015.

An Italian research team demonstrated that miR-9 is up-regulated in two types of human immune cells during the pro-inflammatory process and may regulate a NF-kappa-B subunit.

Strands: Mar 12, 2009

Premium

Rosetta Genomics, Alnylam Pharmaceuticals, Massachusetts Institute of Technology

The company is looking to differentiate itself from other players in the miRNA array market — such as Agilent Technologies, Life Technologies, Exiqon, and Febit — by stressing the "quality, performance, and affordability" of its OneArray platform.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.